Skip to content

Hero image: A transplant and reproductive medicine team discussing a complex care plan with a patient

All insights

Specialist & Emerging Care

Uterus Transplantation: A Real Path to Birth With Extraordinary Clinical Demands

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based review of uterus transplantation, eligibility, IVF, donor and recipient risks, outcomes, ethics, access and experimental status.

Evidence at a glance

47.4%

recipients with at least one live birth in the international registry cohort

The 2000 to 2024 registry reported at least one live birth after 36 of 76 transplants performed before July 2023. Outcomes reflect specialised programmes and selected patients.

Second Report of the International Society of Uterus Transplantation Registry

The indication is absolute uterine-factor infertility

Uterus transplantation is intended for selected people who cannot carry a pregnancy because the uterus is absent or non-functional. Causes can include congenital absence, hysterectomy or severe acquired uterine damage. It does not treat ovarian-factor infertility. The recipient's own or donor oocytes are fertilised through IVF and embryos are created and assessed before or around the transplant pathway.

ASRM recognises uterus transplantation as the first successful medical treatment that can allow gestation in absolute uterine-factor infertility, while describing it as highly experimental and recommending performance within an ethics-approved research protocol [1]. Alternatives may include gestational-carrier arrangements, adoption or deciding not to pursue parenthood, depending on personal values and local law. Counselling must present these options without ranking family legitimacy.

  • Confirm the uterine indication and ovarian or embryo plan separately.
  • Discuss alternatives and local legal availability before enrolment.
  • Use an independent psychosocial and ethics process, not only surgical consent.

This is a multi-stage transplant and fertility pathway

The pathway can involve ovarian stimulation and IVF, recipient evaluation, living- or deceased-donor procurement, transplant surgery, immunosuppression, surveillance biopsies, embryo transfer, high-risk pregnancy, caesarean delivery and later graft hysterectomy. The transplant is temporary by design in many protocols so immunosuppression can end after the intended births. Each stage can fail independently.

A 2024 JAMA report from the Dallas Uterus Transplant Study described 20 recipients, with 14 achieving at least one live birth [2]. That high success comes from a specialised centre and selected cohort and should not be presented as a universal rate. The international registry reported 44 live births from 36 recipients among 76 transplants performed before July 2023, an at-least-one-live-birth rate of 47.4% per transplant [3].

  • Ask for outcomes per attempted transplant, functioning graft and embryo transfer.
  • Separate surgical success from live birth and neonatal outcomes.
  • Plan the timing and criteria for graft removal.

Risk extends to donor, recipient and child

Living donation exposes a healthy donor to major pelvic surgery, including bleeding, urinary-tract injury, infection, thrombosis and long recovery. Deceased donation avoids donor surgical risk but has different logistical and graft considerations. Donor voluntariness must be protected from family pressure, and donor care should be clinically independent from the recipient team.

Recipients face major surgery, graft thrombosis or failure, rejection, infection, immunosuppressive toxicity and further surgery. Pregnancy is treated as high risk, with reported hypertensive, preterm and delivery complications in published series. Caesarean birth is required because the transplanted uterus and vascular connections need protection. Long-term child data remain limited because the first live birth occurred in 2014 [1][2].

  • Provide donor-specific and recipient-specific risk counselling.
  • Include maternal-fetal medicine, transplant medicine and neonatology from the outset.
  • Commit to long-term follow-up of donor, recipient and children with consent.

Success metrics need an honest denominator

A programme can report graft survival, menstruation, embryo-transfer pregnancy, live birth or neonatal survival. These measures answer different questions. The denominator may be screened candidates, enrolled recipients, attempted transplants, technically successful grafts or embryo transfers. Reporting only the most favourable denominator can materially mislead patients.

The registry's 47.4% at-least-one-live-birth estimate includes both living- and deceased-donor transplants completed before a cut-off, and outcomes may change with programme maturity [3]. Centres should publish graft failures, serious adverse events, donor harms, pregnancy complications, preterm birth, child outcomes and loss to follow-up. Individual counselling also needs the person's embryo number and quality, age and comorbidities.

  • Request the complete flow from screening to live birth.
  • Report donor complications with the same visibility as recipient births.
  • Avoid comparing transplant live birth directly with routine IVF without matched context.

Access, ethics and regulation remain unsettled

Uterus transplantation requires transplant infrastructure, advanced reproductive medicine and prolonged multidisciplinary care. ASRM describes it as an experimental procedure that should occur under an institutional review board-approved research protocol [1], while registry data show that practice remains concentrated in specialist centres [3]. Cost and scarcity raise questions about public funding, donor selection, geographic access and fair eligibility. Research protocols may exclude people based on age, medical risk, embryo status or local regulation. Those criteria should be explicit, evidence-informed and independently reviewed.

A realistic digital care system can coordinate pathology, immunosuppression, biopsy, embryo, pregnancy and donor follow-up across institutions. It must not turn a rare experimental pathway into direct-to-consumer marketing. Decision support should display uncertainty, research status and centre-specific outcomes. No patient should infer that platform availability means clinical eligibility or national legal approval.

  • Confirm research, regulatory and reimbursement status in the treatment country.
  • Require independent donor advocacy and conflict-of-interest management.
  • Keep experimental status visible in every patient-facing pathway.

What the evidence cannot yet answer

  • Evidence comes from small, highly selected cohorts in specialised centres with evolving protocols.
  • Long-term outcomes for living donors, recipients and children remain limited.
  • Registry denominators, follow-up periods and programme experience differ, limiting direct comparison.

Questions worth taking into care

  1. What is this centre's live-birth rate per attempted transplant, and what are its serious adverse events?
  2. How are living donors independently evaluated and protected?
  3. How many IVF cycles and embryos are required before transplantation?
  4. What immunosuppression, biopsy, pregnancy and graft-removal plan is used?
  5. Is treatment available only within a research protocol, and who funds long-term follow-up?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    ASRM Position Statement on Uterus Transplantation

    American Society for Reproductive Medicine · 2018

  2. [2]
  3. [3]
  4. [4]
  5. [5]
Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.